NCT01804543View on ClinicalTrials.gov

Impact of Ranolazine on Myocardial Ischemia Detected by High-Field 3T Cardiovascular Magnetic Resonance (CMR) Imaging and P-31 Spectroscopy

UnknownOBSERVATIONAL

Enrollment

30

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2014

Conditions

AnginaHeart Disease

Interventions

DRUG

Ranolazine

ranolazine 500 mg, then 1000 mg twice a day

Trial Locations (1)

90211

RECRUITING

Westside Medical Associates of Los Angeles, Beverly Hills

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Gilead Sciences

INDUSTRY

lead

Westside Medical Associates of Los Angeles

OTHER